Imprimis Pharma (IMMY) Reports Q4 Loss of $0.30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq futures sink as Amazon, Intel intensify AI spending fears
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts IMMY Hot Sheet
Join SI Premium – FREE
Imprimis Pharma (NASDAQ: IMMY) reported Q4 EPS of ($0.30), versus ($0.21) reported last year.
For earnings history and earnings-related data on Imprimis Pharma (IMMY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Chevron beats estimates as refining margins lift earnings
- OmniAb (OABI) Reports In-Line Q3 EPS
- AbbVie (ABBV) Tops Q3 EPS by 8c, Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
